Clare L. Scott - Publications, H-index & Citations

Back

Clare L. Scott

walter and eliza hall institute of medical research, parkville, vic, australia

81H-index

503Paper Count

3.9WCitation Count

Published Papers 125

Publication Date

HCMV as an Oncomodulatory Virus in Ovarian Cancer: Implications of Viral Strain Heterogeneity, Immunomodulation, and Inflammation on the Tumour Microenvironment and Ovarian Cancer Progression

Biomolecules 2025, Vol. 15, Page 1685

IF4.8

2025-12-02

OAAI

Chrissie Giatrakis; Apriliana E. R. Kartikasari; Thomas A. Angelovich; Katie L. Flanagan; Melissa J. Churchill; Clare L. Scott; Srinivasa Reddy Telukutla; Magdalena Plebanski

Save

Genomics of uterine malignancies and the potential of precision medicine

Therapeutic Advances in Medical Oncology

IF4.2

2025-11-24

OAAI

Joseph Polidano; Andrew Jarratt; Clare L. Scott; Holly E. Barker

Save

Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial

Nature Communications

IF15.7

2025-11-05

OAAI

Chee Khoon Lee; Apriliana E. R. Kartikasari; Nirashaa T. Bound; Katherine E. Francis; Kristy Shield-Artin; Justin Bedo; Ksenija Nesic; Katrina Diamante; Rachel L. O’Connell; Mutsa Madondo; Momodou Cox; Claire Davies; Cyril Deceneux; Georgia Goodchild; Andrew Jarratt; Emily Cassar; Hina Amer; U. G. Imalki U. Kariyawasam; Yeh Chen Lee; Janine Lombard; Sally Baron-Hay; Yoland Antill; Catherine Shannon; Sudarshan Selva-Nayagam; Philip Beale; Danka Zebic; Sandy Simon; Anneliese Linaker; Michael A. Quinn; Anthony T. Papenfuss; Matthew J. Wakefield; Cassandra J. Vandenberg; Michael Friedlander; Clare L. Scott; Magdalena Plebanski

Save

Genomics of cervical, vulvar and vaginal cancers and the potential of precision medicine

Therapeutic Advances in Medical Oncology

IF4.2

2025-09-28

OAAI

Holly E. Barker; Joseph Polidano; Andrew Jarratt; Clare L. Scott

Save

Barriers and Breakthroughs in Precision Oncology: A National Registry Study of BRCA Testing and PARP Inhibitor Uptake in Women from the National Gynae-Oncology Registry (NGOR)

Cancers 2025, Vol. 17, Page 2541

IF4.4

2025-08-20

PREAI

Mahendra Naidoo; Clare L Scott; Mike Lloyd; Orla McNally; Robert Rome; Sharnel Perera; John R Zalcberg

Save

Real-world ovarian cancer care and its survival impact on older adults: An observational study from the Australian National Gynae-Oncology Registry (NGOR)

Journal of Geriatric Oncology

IF2.7

2025-07-09

OAAI

Mahendra Naidoo; Clare L. Scott; Orla McNally; Robert Rome; Sharnel Perera; John Zalcberg

Save

Interleukin-6 Is a Crucial Factor in Shaping the Inflammatory Tumor Microenvironment in Ovarian Cancer and Determining Its Hot or Cold Nature with Diagnostic and Prognostic Utilities

CANCERS

IF4.4

2025-05-17

OAAI

Amer, Hina; Flanagan, Katie L.; Kampan, Nirmala C.; Itsiopoulos, Catherine; Scott, Clare L.; Kartikasari, Apriliana E. R.; Plebanski, Magdalena

Save

The antibody-drug conjugate targeting ROR1, NBE-002, is active in high-grade serous ovarian cancer preclinical models

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY

IF4.2

2025-04-21

OAAI

Dongli Liu; Cassandra J. Vandenberg; Patrizia Sini; Lorenz Waldmeier; Rosa Baumgartinger; Laura Pisarsky; Georg Petroczi; Gayanie Ratnayake; Clare L. Scott; Caroline E. Ford

Save

Farletuzumab ecteribulin and MORAb-109, folate receptor alpha and mesothelin targeting antibody-drug conjugates, show activity in poor prognosis gynaecological cancer models

CLINICAL AND TRANSLATIONAL MEDICINE

IF6.8

2025-03-12

OAAI

Nesic, Ksenija; Rybinski, Katherine; Ratnayake, Gayanie; Ho, Gwo-Yaw; Lim, Ratana; Radke, Marc; Neagle, Chloe; Swisher, Elizabeth M.; Wakefield, Matthew J.; Barker, Holly E.; Furuuchi, Keiji; Scott, Clare L.; Vandenberg, Cassandra J.

Save

Phase II randomized study of dostarlimab alone or with bevacizumab versus non-platinum chemotherapy in recurrent gynecological clear cell carcinoma (DOVE/APGOT-OV7/ENGOT-ov80)

JOURNAL OF GYNECOLOGIC ONCOLOGY

IF3.7

2025-01-01

PREAI

Lee, Jung-Yun; Tan, David; Ray-Coquard, Isabelle; Lee, Jung Bok; Kim, Byoung Gie; Van Nieuwenhuysen, Els; Huang, Ruby Yun-Ju; Tse, Ka Yu; Gonzalez-Martin, Antonio; Scott, Clare; Hasegawa, Kosei; Wilkinson, Katie; Yang, Eun Yeong; Lheureux, Stephanie; Kristeleit, Rebecca

Save

How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

IF4.7

2024-12-01

PREAI

Haggstrom, Lucy; Lee, Yeh Chen; Scott, Clare; Harter, Philipp; Woelber, Linn; Gourley, Charlie; McNeish, Iain A.; Ray-Coquard, Isabelle; Leary, Alexandra; Oza, Amit M.; Tinker, Anna; Gonzalez Martin, Antonio; Cecere, Sabrina Chiara; Pignata, Sandro; Colombo, Nicoletta; Yoshida, Hiroyuki; Marth, Christian; Rosengarten, Ora; Moore, Kathleen Nadine; Gomez-Garcia, Eva Maria; Tan, David

Save

Impact of chemotherapy on patients with mismatch repair deficient advanced endometrial carcinomas-a meta-analysis

JNCI CANCER SPECTRUM

IF4.1

2024-10-21

OAAI

Tjokrowidjaja, Angelina; Kok, Peey-Sei; Antill, Yoland C.; Scott, Clare L.; Mileshkin, Linda R.; Friedlander, Michael L.; Lee, Chee K.

Save

How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in platinum sensitive recurrent ovarian cancer and long-term outcomes

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Haggstrom, L. R.; Lee, Y. C.; Scott, C. L.; Ledermann, J. A.; Gourley, C.; McNeish, I.; Amant, F.; Ray-Coquard, I. L.; Leary, A.; Oza, A. M.; Tinker, A.; Gonzalez-Martin, A.; Cecere, S. C.; Colombo, N.; Yoshida, H.; Marth, C.; Gomez Garcia, E. M.; Tan, D. S.; Moore, K. N.; Friedlander, M. L.

Save

SOLACE2: A phase II randomized trial of olaparib (O) and durvalumab (D) with or without low dose cyclophosphamide (LDCy) in platinum-sensitive recurrent ovarian cancer (PSROC)

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Scott, C. L.; Friedlander, M. L.; Francis, K.; Kartikasari, A. E. R.; Diamante, K.; Bound, N.; Davies, C.; O'Connell, R.; Lee, Y. C.; Lombard, J.; Baron-Hay, S. E.; Antill, Y.; Shannon, C.; Selva-Nayagam, S.; Beale, P. J.; Shield-Artin, K.; Wakefield, M.; Vandenberg, C.; Plebanski, M.; Lee, C. K.

Save

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance

MOLECULAR CANCER

IF33.9

2024-08-05

OAAI

Nesic, Ksenija; Krais, John J.; Wang, Yifan; Vandenberg, Cassandra J.; Patel, Pooja; Cai, Kathy Q.; Kwan, Tanya; Lieschke, Elizabeth; Ho, Gwo-Yaw; Barker, Holly E.; Bedo, Justin; Casadei, Silvia; Farrell, Andrew; Radke, Marc; Shield-Artin, Kristy; Penington, Jocelyn S.; Geissler, Franziska; Kyran, Elizabeth; Betsch, Robert; Xu, Lijun; Zhang, Fan; Dobrovic, Alexander; Olesen, Inger; Kristeleit, Rebecca; Oza, Amit; McNeish, Iain; Ratnayake, Gayanie; Traficante, Nadia; DeFazio, Anna; Bowtell, David D. L.; Harding, Thomas C.; Lin, Kevin; Swisher, Elizabeth M.; Kondrashova, Olga; Scott, Clare L.; Johnson, Neil; Wakefield, Matthew J.

Save

High-level tumour methylation of BRCA1 and RAD51C is required for homologous recombination deficiency in solid cancers

NAR CANCER

IF3.2

2024-07-25

OAAI

Xu, Lijun; Liddell, Brett; Nesic, Ksenija; Geissler, Franziska; Ashwood, Lauren M.; Wakefield, Matthew J.; Scott, Clare L.; Waddell, Nicola; Kondrashova, Olga

Save

A risk-reward examination of sample multiplexing reagents for single cell RNA-Seq

GENOMICS

IF3

2024-03-01

OAAI

Brown, Daniel, V; Anttila, Casey J. A.; Ling, Ling; Grave, Patrick; Baldwin, Tracey M.; Munnings, Ryan; Farchione, Anthony J.; Bryant, Vanessa L.; Dunstone, Amelia; Biben, Christine; Taoudi, Samir; Weber, Tom S.; Naik, Shalin H.; Hadla, Anthony; Barker, Holly E.; Vandenberg, Cassandra J.; Dall, Genevieve; Scott, Clare L.; Moore, Zachery; Whittle, James R.; Freytag, Saskia; Best, Sarah A.; Papenfussa, Anthony T.; Olechnowicza, Sam W. Z.; Macrailda, Sarah E.; Wilcox, Stephen; Hickey, Peter F.; Amann-Zalcenstein, Daniela; Bowden, Rory

Save

The role of aberrant DNA methylation in cancer initiation and clinical impacts

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY

IF4.2

2024-01-28

OAAI

Geissler, Franziska; Nesic, Ksenija; Kondrashova, Olga; Dobrovic, Alexander; Swisher, Elizabeth M.; Scott, Clare L.; J. Wakefield, Matthew

Save

Patient and public involvement in preclinical and medical research: Evaluation of an established programme in a Discovery-Based Medical Research Institute

HEALTH EXPECTATIONS

IF3.2

2024-01-19

OAAI

Smith, Robyn A.; Slocombe, Judith; Cockwill, Jo; Minas, Kathy; Kiossoglou, George; Gray, Katya; Lawrence, William; Iddles, Michelle; Scott, Clare; O'Reilly, Lorraine A.

Save

Molecular profiling of p53 mutant endometrial cancer reveals distinct subgroups with opportunities for personalized therapeutic approaches

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

OAAI

Blanc-Durand, F.; Kramer, C.; Rouleau, E.; Vasseur, D.; Bosse, T.; de Boer, S.; Edmondson, R.; Powell, M.; Crosbie, E.; Singh, N.; McAlpine, J.; Mackay, H.; Pollock, P.; Mileshkin, L.; Scott, C. L.; Ngoi, N. Y. L.; Lim, Y. W.; Lim, S. E.; Tan, D. S.; Leary, A.

Save

Research Directions